Search

Your search keyword '"Velasquez, M. Paulina"' showing total 30 results
Start Over Author "Velasquez, M. Paulina"
30 results on '"Velasquez, M. Paulina"'

5. Memory T-cell enriched haploidentical transplantation with NK cell addback results in promising long-term outcomes: a phase II trial

Author

Naik, Swati, Li, Ying, Talleur, Aimee C., Selukar, Subodh, Ashcraft, Emily, Cheng, Cheng, Madden, Renee M., Mamcarz, Ewelina, Qudeimat, Amr, Sharma, Akshay, Srinivasan, Ashok, Suliman, Ali Y., Epperly, Rebecca, Obeng, Esther A., Velasquez, M. Paulina, Langfitt, Deanna, Schell, Sarah, Métais, Jean-Yves, Arnold, Paula Y., Hijano, Diego R., Maron, Gabriela, Merchant, Thomas E., Akel, Salem, Leung, Wing, Gottschalk, Stephen, and Triplett, Brandon M.

Published
2024
Full Text
View/download PDF

6. Stromal-induced epithelial-mesenchymal transition induces targetable drug resistance in acute lymphoblastic leukemia

Author

Park, Chun Shik, Yoshihara, Hiroki, Gao, Qingsong, Qu, Chunxu, Iacobucci, Ilaria, Ghate, Pankaj S., Connelly, Jon P., Pruett-Miller, Shondra M., Wagner, Ben, Robinson, Camenzind G., Mishra, Ashutosh, Peng, Junmin, Yang, Lei, Rankovic, Zoran, Finkelstein, David, Luger, Selina, Litzow, Mark, Paietta, Elisabeth M., Hebbar, Nikhil, Velasquez, M. Paulina, and Mullighan, Charles G.

Published
2023
Full Text
View/download PDF

8. Engineering naturally occurring CD7− T cells for the immunotherapy of hematological malignancies

Author

Freiwan, Abdullah, Zoine, Jaquelyn T., Crawford, Jeremy Chase, Vaidya, Abishek, Schattgen, Stefan A., Myers, Jacquelyn A., Patil, Sagar L., Khanlari, Mahsa, Inaba, Hiroto, Klco, Jeffery M., Mullighan, Charles G., Krenciute, Giedre, Chockley, Peter J., Naik, Swati, Langfitt, Deanna M., Mamonkin, Maksim, Obeng, Esther A., Thomas, Paul G., Gottschalk, Stephen, and Velasquez, M. Paulina

Published
2022
Full Text
View/download PDF

9. Preferential expansion of CD8+ CD19-CAR T cells postinfusion and the role of disease burden on outcome in pediatric B-ALL

Author

Talleur, Aimee C., Qudeimat, Amr, Métais, Jean-Yves, Langfitt, Deanna, Mamcarz, Ewelina, Crawford, Jeremy Chase, Huang, Sujuan, Cheng, Cheng, Hurley, Caitlin, Madden, Renee, Sharma, Akshay, Suliman, Ali, Srinivasan, Ashok, Velasquez, M. Paulina, Obeng, Esther A., Willis, Catherine, Akel, Salem, Karol, Seth E., Inaba, Hiroto, Bragg, Allison, Zheng, Wenting, Zhou, Sheng M., Schell, Sarah, Tuggle-Brown, MaCal, Cullins, David, Patil, Sagar L, Li, Ying, Thomas, Paul G., Zebley, Caitlin, Youngblood, Benjamin, Pui, Ching-Hon, Lockey, Timothy, Geiger, Terrence L., Meagher, Michael M., Triplett, Brandon M., and Gottschalk, Stephen

Published
2022
Full Text
View/download PDF

11. Supplementary Data from Common Trajectories of Highly Effective CD19-Specific CAR T Cells Identified by Endogenous T-cell Receptor Lineages

Author

Wilson, Taylor L., primary, Kim, Hyunjin, primary, Chou, Ching-Heng, primary, Langfitt, Deanna, primary, Mettelman, Robert C., primary, Minervina, Anastasia A., primary, Allen, E. Kaitlynn, primary, Métais, Jean-Yves, primary, Pogorelyy, Mikhail V., primary, Riberdy, Janice M., primary, Velasquez, M. Paulina, primary, Kottapalli, Pratibha, primary, Trivedi, Sanchit, primary, Olsen, Scott R., primary, Lockey, Timothy, primary, Willis, Catherine, primary, Meagher, Michael M., primary, Triplett, Brandon M., primary, Talleur, Aimee C., primary, Gottschalk, Stephen, primary, Crawford, Jeremy Chase, primary, and Thomas, Paul G., primary

Published
2023
Full Text
View/download PDF

12. Data from Common Trajectories of Highly Effective CD19-Specific CAR T Cells Identified by Endogenous T-cell Receptor Lineages

Author

Wilson, Taylor L., primary, Kim, Hyunjin, primary, Chou, Ching-Heng, primary, Langfitt, Deanna, primary, Mettelman, Robert C., primary, Minervina, Anastasia A., primary, Allen, E. Kaitlynn, primary, Métais, Jean-Yves, primary, Pogorelyy, Mikhail V., primary, Riberdy, Janice M., primary, Velasquez, M. Paulina, primary, Kottapalli, Pratibha, primary, Trivedi, Sanchit, primary, Olsen, Scott R., primary, Lockey, Timothy, primary, Willis, Catherine, primary, Meagher, Michael M., primary, Triplett, Brandon M., primary, Talleur, Aimee C., primary, Gottschalk, Stephen, primary, Crawford, Jeremy Chase, primary, and Thomas, Paul G., primary

Published
2023
Full Text
View/download PDF

13. Supplementary Figure from Common Trajectories of Highly Effective CD19-Specific CAR T Cells Identified by Endogenous T-cell Receptor Lineages

Author

Wilson, Taylor L., primary, Kim, Hyunjin, primary, Chou, Ching-Heng, primary, Langfitt, Deanna, primary, Mettelman, Robert C., primary, Minervina, Anastasia A., primary, Allen, E. Kaitlynn, primary, Métais, Jean-Yves, primary, Pogorelyy, Mikhail V., primary, Riberdy, Janice M., primary, Velasquez, M. Paulina, primary, Kottapalli, Pratibha, primary, Trivedi, Sanchit, primary, Olsen, Scott R., primary, Lockey, Timothy, primary, Willis, Catherine, primary, Meagher, Michael M., primary, Triplett, Brandon M., primary, Talleur, Aimee C., primary, Gottschalk, Stephen, primary, Crawford, Jeremy Chase, primary, and Thomas, Paul G., primary

Published
2023
Full Text
View/download PDF

15. Venetoclax-based therapy as a bridge to allogeneic hematopoietic cell transplantation in children with relapsed/refractory AML

Author

Pfeiffer, Thomas, primary, Li, Ying, additional, Ashcraft, Emily, additional, Karol, Seth E., additional, Rubnitz, Jeffrey E., additional, Epperly, Rebecca, additional, Madden, Renee, additional, Mamcarz, Ewelina, additional, Obeng, Esther, additional, Qudeimat, Amr, additional, Sharma, Akshay, additional, Srinivasan, Ashok, additional, Suliman, Ali, additional, Talleur, Aimee C., additional, Velasquez, M. Paulina, additional, Gottschalk, Stephen, additional, Triplett, Brandon M., additional, and Naik, Swati, additional

Published
2022
Full Text
View/download PDF

18. Common Trajectories of Highly Effective CD19-Specific CAR T Cells Identified by Endogenous T-cell Receptor Lineages

Author

Wilson, Taylor L., primary, Kim, Hyunjin, additional, Chou, Ching-Heng, additional, Langfitt, Deanna, additional, Mettelman, Robert C., additional, Minervina, Anastasia A., additional, Allen, E. Kaitlynn, additional, Métais, Jean-Yves, additional, Pogorelyy, Mikhail V., additional, Riberdy, Janice M., additional, Velasquez, M. Paulina, additional, Kottapalli, Pratibha, additional, Trivedi, Sanchit, additional, Olsen, Scott R., additional, Lockey, Timothy, additional, Willis, Catherine, additional, Meagher, Michael M., additional, Triplett, Brandon M., additional, Talleur, Aimee C., additional, Gottschalk, Stephen, additional, Crawford, Jeremy Chase, additional, and Thomas, Paul G., additional

Published
2022
Full Text
View/download PDF

20. Development of a cGMP-compliant process to manufacture donor-derived, CD45RA-depleted memory CD19-CAR T cells

Author

Kim-Hoehamer, Young-In, primary, Riberdy, Janice M., additional, Zheng, Fei, additional, Park, Jeoungeun J., additional, Shang, Na, additional, Métais, Jean-Yves, additional, Lockey, Timothy, additional, Willis, Catherine, additional, Akel, Salem, additional, Moore, Jennifer, additional, Meagher, Michael M., additional, Velasquez, M. Paulina, additional, Triplett, Brandon M., additional, Talleur, Aimee C., additional, Gottschalk, Stephen, additional, and Zhou, Sheng, additional

Published
2022
Full Text
View/download PDF

23. Engineering naturally occurring CD7−T cells for the immunotherapy of hematological malignancies

Author

Freiwan, Abdullah, Zoine, Jaquelyn T., Crawford, Jeremy Chase, Vaidya, Abishek, Schattgen, Stefan A., Myers, Jacquelyn A., Patil, Sagar L., Khanlari, Mahsa, Inaba, Hiroto, Klco, Jeffery M., Mullighan, Charles G., Krenciute, Giedre, Chockley, Peter J., Naik, Swati, Langfitt, Deanna M., Mamonkin, Maksim, Obeng, Esther A., Thomas, Paul G., Gottschalk, Stephen, and Velasquez, M. Paulina

Abstract

•Naturally occurring CD7 negative T cells are functional effector T cells that can be used for chimeric antigen receptor therapy.•CD7 negative T cells expressing a CD7-CAR have robust antitumor activity and bypass fratricide.

Published
2022
Full Text
View/download PDF

24. Preferential expansion of CD8+CD19-CAR T cells postinfusion and the role of disease burden on outcome in pediatric B-ALL

Author

Talleur, Aimee C., Qudeimat, Amr, Métais, Jean-Yves, Langfitt, Deanna, Mamcarz, Ewelina, Crawford, Jeremy Chase, Huang, Sujuan, Cheng, Cheng, Hurley, Caitlin, Madden, Renee, Sharma, Akshay, Suliman, Ali, Srinivasan, Ashok, Velasquez, M. Paulina, Obeng, Esther A., Willis, Catherine, Akel, Salem, Karol, Seth E., Inaba, Hiroto, Bragg, Allison, Zheng, Wenting, Zhou, Sheng M., Schell, Sarah, Tuggle-Brown, MaCal, Cullins, David, Patil, Sagar L, Li, Ying, Thomas, Paul G., Zebley, Caitlin, Youngblood, Benjamin, Pui, Ching-Hon, Lockey, Timothy, Geiger, Terrence L., Meagher, Michael M., Triplett, Brandon M., and Gottschalk, Stephen

Abstract

•CD8+CD19-CAR T cells outcompete their CD4+counterparts and undergo antigen-driven differentiation after infusion.•Our study highlights the role of disease burden on outcome after CD19-CAR T-cell therapy.

Published
2022
Full Text
View/download PDF

29. Chimeric antigen receptor T-cell therapy in childhood acute myeloid leukemia: how far are we from a clinical application?

Author

Naik S, Velasquez MP, and Gottschalk S

Subjects
Humans, Child, Clinical Trials as Topic, T-Lymphocytes immunology, T-Lymphocytes metabolism, Treatment Outcome, Receptors, Antigen, T-Cell immunology, Receptors, Antigen, T-Cell genetics, Tumor Microenvironment immunology, Animals, Leukemia, Myeloid, Acute therapy, Leukemia, Myeloid, Acute immunology, Receptors, Chimeric Antigen immunology, Immunotherapy, Adoptive methods
Abstract

Recurrent and/or refractory (R/R) pediatric acute myeloid leukemia (AML) remains a recalcitrant disease with poor outcomes. Cell therapy with genetically modified immune effector cells holds the promise to improve outcomes for R/R AML since it relies on cytotoxic mechanisms that are distinct from chemotherapeutic agents. While T cells expressing chimeric antigen receptors (CAR T cells) showed significant anti-AML activity in preclinical models, early phase clinical studies have demonstrated limited activity, irrespective of the targeted AML antigen. Lack of efficacy is most likely multifactorial, including: (i) a limited array of AML-specific targets and target antigen heterogeneity; (ii) the aggressive nature of R/R AML and heavy pretreatment of patients; (iii) T-cell product manufacturing, and (iv) limited expansion and persistence of the CAR T cells, which is in part driven by the immunosuppressive AML microenvironment. Here we review the results of early phase clinical studies with AML-specific CAR T cells, and avenues investigators are exploring to improve their effector function.

Published
2024
Full Text
View/download PDF

30. Improving the anti-acute myeloid leukemia activity of CD123-specific engager T cells by MyD88 and CD40 costimulation.

Author

Vaidya A, Doherty E, Wu X, Huang S, Hebbar N, Thanekar U, Bonifant CL, Cheng C, Gottschalk S, and Velasquez MP

Subjects
Animals, Humans, Mice, Cell Line, Tumor, Interleukin-3 Receptor alpha Subunit metabolism, Myeloid Differentiation Factor 88 genetics, Myeloid Differentiation Factor 88 metabolism, CD40 Antigens metabolism, Leukemia, Myeloid, Acute metabolism, T-Lymphocytes metabolism
Abstract

The outcome of patients with acute myeloid leukemia remains poor, and immunotherapy has the potential to improve this. T cells expressing chimeric antigen receptors or bispecific T-cell engagers targeting CD123 are actively being explored in preclinical and/or early phase clinical studies. We have shown that T cells expressing CD123-specific bispecific T-cell engagers (CD123.ENG T cells) have anti-acute myeloid leukemia activity. However, like chimeric antigen receptor T cells, their effector function diminishes rapidly once they are repeatedly exposed to antigen-positive target cells. Here we sought to improve the effector function of CD123.ENG T cells by expressing inducible co-stimulatory molecules consisting of MyD88 and CD40 (iMC), MyD88 (iM), or CD40 (iC), which are activated by a chemical inducer of dimerization. CD123.ENG T cells expressing iMC, iM, or iC maintained their antigen specificity in the presence of a chemical inducer of dimerization, as judged by cytokine production (interferon-γ, interleukin-2) and their cytolytic activity. In repeat stimulation assays, activating iMC and iM, in contrast to iC, enabled CD123.ENG T cells to secrete cytokines, expand, and kill CD123-positive target cells repeatedly. Activating iMC in CD123.ENG T cells consistently improved antitumor activity in an acute myeloid leukemia xenograft model. This translated into a significant survival advantage in comparison to that of mice that received CD123.ENG or CD123.ENG.iC T cells. In contrast, activation of only iM in CD123.ENG T cells resulted in donor-dependent antitumor activity. Our work highlights the need for both toll-like receptor pathway activation via MyD88 and provision of co-stimulation via CD40 to consistently enhance the antitumor activity of CD123.ENG T cells.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results